Monitor the next 10-Q filing for updates on remediation of the material weakness and any further auditor-related disclosures. The appointment of EY may improve audit credibility, but the pattern of auditor changes warrants close attention to financial reporting quality.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $8.47entry
- T+1 · 5mo ago +3.31%α +3.44% · $8.75
- T+5 · 4mo ago +4.72%α +4.46% · $8.87
- T+20 · 4mo ago −15.11%α −12.93% · $7.19
- T+60 · 8w ago −8.26%α −11.22% · $7.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independent registered public accounting firm for FY2026. The change was approved by the Audit Committee on June 25, 2026, with no disagreements between the company and CBIZ, though a previously disclosed material weakness in internal controls over financial reporting was noted as a reportable event. The move from a mid-tier firm to a Big 4 auditor may signal a step up in audit quality, but the second auditor change in just over a year and the existing material weakness warrant caution.
Key Facts
- CorMedix dismissed CBIZ CPAs P.C. as its independent auditor on June 25, 2026.
- Appointed Ernst & Young LLP (EY) as the new independent auditor for the fiscal year ending December 31, 2026.
- No disagreements (as defined in Item 304(a)(1)(iv)) occurred with CBIZ from April 17, 2025 through June 25, 2026.
- A material weakness in internal control over financial reporting was disclosed as a reportable event, previously reported in the FY2025 10-K.
- CBIZ agreed with the statements in the 8-K via Exhibit 16.1 letter dated July 1, 2026.
Financial Impact
No financial figures provided; the change in auditor does not directly impact reported financials.
Risk Factors
- Continued material weakness in internal controls could lead to restatements or delayed filings.
- Further auditor changes may signal underlying accounting or governance issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001410098-26-000037 |
| Exhibit: exhibit161letterfromcbiz.htm | 0001410098-26-000037 |
| Document: 0001410098-26-000037-index-headers.html | 0001410098-26-000037 |
| Document: 0001410098-26-000037-index.html | 0001410098-26-000037 |
| Document: 0001410098-26-000037.txt | 0001410098-26-000037 |
Track record
21 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers